Table 4.

Data summary for candidate efficacy and safety biomarkers in juvenile dermatomyositis.

Protein	Mean RFU’s Pre-treatment	Mean RFU’s Posttreatment	Mean difference Pre- to Post-treatment	Ratio (Post/ Pre)	Longitudinal paired t-test (P-value)	Wilcoxon signed rank test (P-value)
Candidate Efficacy biomarkers
MMP-12	3709	1441	−2268	0.39	0.0057**	0.001***
CD23	11,293	6587	−4706	0.58	0.0013***	0.001***
MDC	2964	2169	−795	0.73	0.0028**	0.0034**
Protein C	1565	1911	346	1.22	0.0015**	0.0034**
IL-22BP	6716	4230	−2486	0.63	0.0068**	0.0024**
LY9	8012	4802	−3210	0.6	0.0005***	0.001***
FGG	13,299	7898	−5401	0.59	0.0726	0.0425*
ANGPT2	410	217	−193	0.53	0.0018**	0.001***
LT a1/b2	576	307	−269	0.53	0.0017**	0.0024**
IGFBP-2	599	295	−304	0.49	0.0172*	0.001***
Integrin A1B1	1963	974	−989	0.5	0.0162*	0.0122**
Candidate Safety biomarkers
Afamin	27,200	34,491	7291	1.27	0.0022**	0.0034**
Leptin	4645	8085	3440	1.74	0.0091**	0.0068**
Angiotensinogen	5876	6949	1073	1.18	0.0009***	0.0015**
MMP-3	936	3256	2320	3.48	0.0171*	0.001***
IGFBP-5	1537	1703	166	1.11	0.018*	0.0269*
GHBP	1211	1457	246	1.2	0.0463*	0.064
Insulin	336	470	134	1.4	0.1532	0.2661

^*P-value ≤0.05;

^**P-value ≤0.01;

^***P-value ≤0.001

Abbreviations: MMP12 = matrix metalloproteinase-12; MDC = macrophage derived cytokine; IL-22 BP = interleukin-22 binding protein; LY9 = T lymphocyte antigen Ly9; FGG = fibrinogen gamma chain; ANGPT2 = angiopoietin-2; LT a1/b2 = lymphotoxin a1/b2; IGFBP-2 = insulin-like growth factor binding protein-2; ITGA1 ITGB1 = integrin A1 B1; MMP-3 = matrix metalloproteinase-3; IGFBP-5 = insulin-like growth factor binding protein-5; GHBP = growth hormone binding protein.